Evidence map›Paper›PMID 40904574›Full record

ArticleFrontiers in psychiatry2025

Diagnosing schizophrenia with routine blood tests: a comparative analysis of machine learning algorithms.

Yavuz Selim Ogur, Ayse Erdogan Kaya, Nur Banu Ogur, Beyza Erdogan Akturk

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yavuz Selim OgurDepartment of Psychiatry, Serdivan State Hospital, Sakarya, Türkiye.
Ayse Erdogan KayaDepartment of Psychiatry, Faculty of Medicine, Hitit University Çorum Erol Olçok Training and Research Hospital, Çorum, Türkiye.
Nur Banu OgurDepartment of Software Engineering, Faculty of Computer and Information Sciences, Sakarya University, Sakarya, Türkiye.
Beyza Erdogan AkturkDepartment of Psychiatry, Tarsus State Hospital, Mersin, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Schizophrenia is a severe mental disorder affecting approximately 1% of the general population, diagnosed primarily using clinical criteria. Due to the lack of objective diagnostic methods and reliable biomarkers, accurate diagnosis and effective treatment remain challenging. Peripheral blood biomarkers have recently attracted attention, and machine learning methods offer promising analytical capabilities to enhance diagnostic accuracy. Methods: This retrospective, case-control study included 203 schizophrenia patients treated over a five-year period at a tertiary hospital and 192 age- and sex-matched healthy controls. Demographic data and routine hematological and biochemical parameters were extracted from medical records. Variables missing more than 85% of data were excluded; remaining missing values were imputed after train-test splitting to avoid data leakage. Optimal biomarker subsets were selected using Grey Wolf Optimization (GWO). Random Forest (RF), XGBoost, Support Vector Machine (SVM), K-Nearest Neighbor (KNN), and Logistic Regression (LR) models were trained and evaluated via stratified 10-fold cross-validation. Results: Groups were homogeneous in terms of age and sex. Before GWO optimization, XGBoost (95.55%) and Random Forest (94.63%) yielded the highest accuracies. Following optimization, Random Forest accuracy improved (94.95%) with a recall of 96.25%, while XGBoost reached the highest accuracy (95.90%) and strong specificity (95.54%). Post-optimization, Area Under the Curve (AUC) values were highest for XGBoost (0.96) and Random Forest (0.95), indicating strong diagnostic performance. Total protein, glucose, iron, creatine kinase, total bilirubin, uric acid, calcium, and sodium were key biomarkers distinguishing schizophrenia. Interestingly, glucose levels were significantly lower in schizophrenia patients compared to controls, contrary to typical findings. Differences in triglycerides, liver enzymes, sodium, and potassium lacked clear clinical significance. Discussion: The machine learning models developed provided diagnostic accuracy comparable to studies utilizing more expensive biomarkers, highlighting potential clinical and economic advantages. External validation is recommended to further confirm the generalizability and clinical utility of these findings.

Indexed as

biomarkersblood parametersgrey wolf optimization (GWO)machine learningschizophrenia

Identifiers

PMID40904574
PMCPMC12401956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.